page header

Contents  ·  Introduction  ·  Learning  Objectives  ·  Textbook  ·  Lectures  ·  Procedures  ·  Final Exam  ·  Library  ·  Laboratory  ·  Pharmacy  ·  Imaging  ·  Forms  ·  Videos  ·  About  ·  Contact Us>

Pelvic Inflammatory  Disease (PID)

Mild PID

Moderate to Severe PID

Military Applications

Pelvic Inflammatory Disease (PID) is a bacterial inflammation of the fallopian tubes, ovaries, uterus and cervix.

Initial infections are caused by single-agent STDs, such as gonorrhea or chlamydia. Subsequent infections are often caused by multiple non-STD organisms (E. Coli, Bacteroides, etc.). Responsible organisms include STDs, normal vaginal inhabitants, and enteric bacteria.

Most cases of PID have no long-term adverse effects, but some have such serious (or disastrous) consequences as infertility, tubo-ovarian abscess, and sepsis. Women with a history of PID are at increased risk for subsequent tubal ectopic pregnancy.

Symptoms of PID vary from nearly trivial pelvic discomfort and vaginal discharge to incapacitating abdominal pain with nausea and vomiting. Leukocytosis, like fever, is variable in cases of PID. The diagnosis can be based on such imprecise findings as uterine and adnexal tenderness without other explanation, or such precise findings as laparoscopic visualization of inflamed tubes with surrounding purulence. Cervical cultures may or may not be positive. Ultrasound findings may be normal or may include a generalized haziness due to edema. In more advanced cases, hydrosalpinx may be seen with ultrasound, CT or MRI.

From a clinical management point of view, there are two forms of PID:

  • Mild, and
  • Moderate to Severe

CDC Treatment Guidelines

Mild PID
Gradual onset of mild bilateral pelvic pain with purulent vaginal discharge is the typical complaint. Fever <100.4 and deep dyspareunia are common.

Moderate pain on motion of the cervix and uterus with purulent or mucopurulent cervical discharge is found on examination. Gram-negative diplococci or positive chlamydia culture may or may not be present. WBC may be minimally elevated or normal. These cases are treated aggressively, but usually with oral medications. Prompt response is expected. Sexual partners should also be treated.

Oral treatment may consist of

Ofloxacin400 mg orally twice a day for 14 days
     OR
Levofloxacin
500 mg orally once daily for 14 days
     WITH or WITHOUT
Metronidazole 500 mg orally twice a day for 14 days.

Another primarily oral regimen is:

Ceftriaxone250 mg IM in a single dose
     OR
Cefoxitin
2 g IM in a single dose and Probenecid, 1 g orally administered concurrently in a single dose
     OR
Other parenteral third-generation cephalosporin (e.g., ceftizoximeor cefotaxime)
    
PLUS
Doxycycline 100 mg orally twice a day for 14 days
     WITH or WITHOUT
Metronidazole 500 mg orally twice a day for 14 days.

For further information, read the CDC Treatment Guidelines for PID

Moderate to Severe PID
With moderate to severe PID, there is a gradual onset of moderate to severe bilateral pelvic pain with purulent vaginal discharge, fever >100.4 (38.0), lassitude, and headache. Symptoms more often occur shortly after the onset or completion of menses.

Excruciating pain on movement of the cervix and uterus is characteristic of this condition. Hypoactive bowel sounds, purulent cervical discharge, and abdominal dissension are often present. Pelvic and abdominal tenderness is always bilateral except in the presence of an IUD.

Gram-negative diplococci in cervical discharge or positive chlamydia culture may or may not be present. WBC and ESR are elevated.

These more serious infections require more aggressive management, often consisting of bedrest, IV fluids, IV antibiotics, and NG suction if ileus is present. A more gradual recovery is expected and it may be several weeks before the patient is feeling normal.


ANTIBIOTIC REGIMEN: (Center for Disease Control, 2002)

Cefotetan2 g IV every 12 hours
     OR
Cefoxitin
2 g IV every 6 hours
     PLUS
Doxycycline 100 mg orally or IV every 12 hours.

The doxycycline is continued for 14 days. The parenteral medication may be stopped 24 hours after clinical improvement.


OTHER ALTERNATIVE ANTIBIOTIC REGIMENS: (Center for Disease Control, 2002)

Clindamycin900 mg IV every 8 hours
     PLUS
Gentamicinloading dose IV or IM (2 mg/kg of body weight) followed by a maintenance dose (1.5 mg/kg) every 8 hours. Single daily dosing may be substituted.


Ofloxacin400 mg IV every 12 hours
     OR
Levofloxacin
500 mg IV once daily
     WITH or WITHOUT
Metronidazole 500 mg IV every 8 hours


Ampicillin/Sulbactam 3 g IV every 6 hours
     PLUS
Doxycycline 100 mg orally or IV every 12 hours.

For further information, read the CDC Treatment Guidelines for PID

Military Applications
PID is a relatively common occurrence in the military population and the advanced settings in which they operate. It is prudent to consider PID whenever presented with a patient complaining of pelvic pain or an unusual vaginal discharge.

In conventional settings, cultures can be very helpful in determining who needs treatment and who doesn't. In forward military settings, treatment must often be based on your clinical suspicions, patient history and operational circumstances. Liberal use of these antibiotics is encouraged.

The problem with moderate to severe PID in a forward setting is that even when things go well, it usually requires prolonged IV antibiotic therapy (weeks) to achieve a cure, and a lengthy recovery (4-6 weeks). When things don't go well, surgical intervention to remove pelvic abscesses is usually required. For these reasons, mild PID is usually treated effectively in the advanced setting, while MEDEVAC is employed for those with moderate to severe PID. A significant fever is characteristic of the moderate to severe PID group.

 


This information is provided by The Brookside Associates.  The Brookside Associates, LLC. is a private organization, not affiliated with any governmental agency. The opinions presented here are those of the author and do not necessarily represent the opinions of the Brookside Associates or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. All material presented here is unclassified.

C. 2009, 2014, All Rights Reserved

brookside associates logo

 

 

 

 

 

 

Advertise on this site